Alphaviruses cause encephalitis in man and animals and are transmitted
by mosquitos. The alphavirus Sindbis infects and kills most cultured cell
types, not by lethal parasitism, but by inducing programmed cell death,
or apoptosis. However, in mosquito cells and in neurons, both in vivo and
in vitro, Sindbis virus can establish a persistent infection in which
virus continues to be produced but the cells survive. These results
indicate that a cellular factor can modulate the outcome of infection.
Neurons express the human oncogene bcl-2 which has been shown to block
apoptosis in a variety of cell types and species. We generated a cell
line expressing bcl-2 and found that it supported Sindbis virus
persistence while controls lacking bcl-2 died. However, neurovirulent
strains of Sindbis virus were able to induce apoptosis despite the
expression of bcl-2. This ability to kill bcl2-containing cells has been
mapped to a single amino acid change in the E2 glycoprotein.
To study Sindbis virus neurovirulence, we will examine the molecular
mechanisms by which viral E2 and cellular bcl-2 modulate the outcome of
Sindbis virus infection. To determine why avirulent strains fail to kill
the cells expressing bcl-2, we will identify the viral infection step
(binding, entry, replication, maturation) which is affected. A battery
of antibodies will be used study the maturation of E2 in bcl-2 positive
and negative cells. In addition we will generate cell lines expressing
bcl-2 mutants and assay the function of these mutants in Sindbis virus
infections. Some effects of bcl-2 can be mimicked by treatment of cells
with antioxidants. Therefore, we will study the effects of these agents
on viral replication and maturation, and on the structure/function of the
E2 glycoprotein.
The mechanisms of Sindbis virus neurovirulence are likely to apply to
other viruses, and an increased understanding of the bcl-2 oncogene has
ramifications for normal cellular processes as well as neurodegenerative
disease.
National Institute of Neurological Disorders and Stroke
CFDA Code
DUNS Number
001910777
UEI
FTMTDMBR29C7
Project Start Date
01-February-1995
Project End Date
31-January-1999
Budget Start Date
01-February-1995
Budget End Date
31-January-1996
Project Funding Information for 1995
Total Funding
$221,522
Direct Costs
$137,229
Indirect Costs
$84,293
Year
Funding IC
FY Total Cost by IC
1995
National Institute of Neurological Disorders and Stroke
$221,522
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01NS034175-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01NS034175-01
Patents
No Patents information available for 1R01NS034175-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01NS034175-01
Clinical Studies
No Clinical Studies information available for 1R01NS034175-01
News and More
Related News Releases
No news release information available for 1R01NS034175-01
History
No Historical information available for 1R01NS034175-01
Similar Projects
No Similar Projects information available for 1R01NS034175-01